During the past decade, Instytut Matki i Dziecka conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 4 clinical trials were completed, i.e. on average, 36.4% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 3 clinical trials were completed. i.e. 42.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Instytut Matki i Dziecka" #1 sponsor was "Anna Raciborska" with 3 trials, followed by "Institute of Mother and Child, Warsaw, Poland" with 2 trials sponsored, "PTC Therapeutics" with 2 trials sponsored, "Amgen" with 1 trials sponsored and "Amzell" with 1 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Instytut Matki i Dziecka" #1 collaborator was "Maria Sklodowska-Curie National Research Institute of Oncology" with 4 trials as a collaborator, "Wrocław University of Environmental and Life Sciences" with 3 trials as a collaborator, "Łukasiewicz Research Network" with 3 trials as a collaborator, "Bielanski Hospital" with 1 trials as a collaborator and "Cystic Fibrosis Foundation" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Instytut Matki i Dziecka" are "Cystic Fibrosis" (4 trials), "Histiocytosis" (3 trials), "Osteosarcoma" (2 trials), "Advanced Solid Tumor" (1 trials) and "Cleft Lip and Palate" (1 trials). Many other conditions were trialed in "Instytut Matki i Dziecka" in a lesser frequency.

Most popular intervention types in "Instytut Matki i Dziecka" are "Drug" (12 trials), "Device" (1 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "AMZ002 injectable solution, 0.5mg/mL" (1 trials), "AZLI" (1 trials), "Ataluren" (1 trials) and "Ataluren (PTC124®)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Instytut Matki i Dziecka" are 13 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Instytut Matki i Dziecka". undefined are not yet recruiting, 7 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Instytut Matki i Dziecka, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Instytut Matki i Dziecka, 2 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".